Bone disease readout sinks Mereo, Ultragenyx shares: Clinical Roundup

Disappointing results in a pair of pivotal studies of setrusumab to treat osteogenesis imperfecta destroyed most of Mereo’s market value on Monday, and nearly halved the market cap of its partner Ultragenyx.

The companies said the sclerostin inhibitor, also known as UX143, missed statistical significance on the primary endpoint of annualized clinical fracture rate in both the Phase II/III ORBIT trial and the pediatric Phase III COSMIC study. Both trials showed significance on a secondary endpoint measuring bone mineral density, with an effect consistent with Phase II results...